A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients (CWP-DIANA-301)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Anagliptin
Anagliptin
Placebo of Anagliptin
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring CWP-0403, type 2 DM, Efficacy, Safety, Phase 3
Eligibility Criteria
Inclusion Criteria:
- Type 2 DM patients
- Subjects who couldn't control the blood glucose despite of a dietary and exercise therapy more than 6 weeks at screening visit
- FPG ≤ 270mg/dL at screening visit
- Patients who consent to participate in this trial by written Informed Consent Form
Exclusion Criteria:
- Type 1 DM or secondary diabetes
- Subjects who are administrating insulin or need to insulin therapy
- History of oral anti-hyperglycemic drugs within 6 weeks before screening visit
- Body mass index < 20 kg/m2 or > 40.0kg/m2
- Subjects who are assessed to be inappropriate for this trial by investigator
Sites / Locations
- Kangbuk Samsung Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Placebo Comparator
Experimental
Experimental
Arm Label
Placebo of CWP-0403 100mg
CWP-0403 200mg
CWP-0403 100mg
Arm Description
Placebo of CWP-0403 100mg
CWP-0403 200mg
CWP-0403 100mg
Outcomes
Primary Outcome Measures
The Change in HbA1c from baseline to week24
Secondary Outcome Measures
The proportion of subjects achieving HbA1c<6.5% at week24
The proportion of subjects achieving HbA1c<7% at week24
The change from baseline to week 24: Fasting plasma glucose
change from baseline to week 24 in Fasting serum insulin
change from baseline to week 24 in Fasting serum pro-insulin
change in from baseline to week 24 fasting serum c-peptide
change from baseline to week 24 in HOMA-β
change from baseline to week 24 in HOMA-IR
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01529528
Brief Title
A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
Acronym
CWP-DIANA-301
Official Title
A Multicenter, Randomized, Double Blind, Placebo Controlled, Therapeutic Confirmatory Trial(Phase 3) to Evaluate Efficacy and Safety of CWP-0403 in Type 2 DM Patients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
November 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
JW Pharmaceutical
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is to evaluate the efficacy and safety of CWP-0403 at 100 mg or 200 mg twice daily compared with placebo in type 2 diabetic patients with inadequate glycemic control by diet therapy or combination of diet and exercise therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
CWP-0403, type 2 DM, Efficacy, Safety, Phase 3
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
117 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo of CWP-0403 100mg
Arm Type
Placebo Comparator
Arm Description
Placebo of CWP-0403 100mg
Arm Title
CWP-0403 200mg
Arm Type
Experimental
Arm Description
CWP-0403 200mg
Arm Title
CWP-0403 100mg
Arm Type
Experimental
Arm Description
CWP-0403 100mg
Intervention Type
Drug
Intervention Name(s)
Anagliptin
Intervention Description
Anagliptin 100mg, tablet, BID
Intervention Type
Drug
Intervention Name(s)
Anagliptin
Intervention Description
Anagliptin 100mg, tablet, BID
Intervention Type
Drug
Intervention Name(s)
Placebo of Anagliptin
Intervention Description
Placebo of Anagliptin 100mg, tablet, BID
Primary Outcome Measure Information:
Title
The Change in HbA1c from baseline to week24
Time Frame
0wk, 8wk, 16wk, 24wk
Secondary Outcome Measure Information:
Title
The proportion of subjects achieving HbA1c<6.5% at week24
Time Frame
0wk, 8wk, 16wk, 24wk
Title
The proportion of subjects achieving HbA1c<7% at week24
Time Frame
0wk, 8wk, 16wk, 24wk
Title
The change from baseline to week 24: Fasting plasma glucose
Time Frame
0wk, 24wk
Title
change from baseline to week 24 in Fasting serum insulin
Time Frame
0 wk, 24 wk
Title
change from baseline to week 24 in Fasting serum pro-insulin
Time Frame
0 wk, 24wk
Title
change in from baseline to week 24 fasting serum c-peptide
Time Frame
0wk, 24wk
Title
change from baseline to week 24 in HOMA-β
Time Frame
owjm 24wk
Title
change from baseline to week 24 in HOMA-IR
Time Frame
0wk, 24 wk
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 DM patients
Subjects who couldn't control the blood glucose despite of a dietary and exercise therapy more than 6 weeks at screening visit
FPG ≤ 270mg/dL at screening visit
Patients who consent to participate in this trial by written Informed Consent Form
Exclusion Criteria:
Type 1 DM or secondary diabetes
Subjects who are administrating insulin or need to insulin therapy
History of oral anti-hyperglycemic drugs within 6 weeks before screening visit
Body mass index < 20 kg/m2 or > 40.0kg/m2
Subjects who are assessed to be inappropriate for this trial by investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sung Woo Park, M.D., PhD
Organizational Affiliation
Kangbuk Samsung Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kangbuk Samsung Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
A Study to Efficacy and Safety of CWP-0403 in Type 2 Diabetes Mellitus Patients
We'll reach out to this number within 24 hrs